The #FDA has started a review of the #marketingapplication for #Takeda's #TYK2inhibitor zasocitinib in #psoriasis, setting up a decision in mid-March 2027.
@pharmaphorum.bsky.socialExplore
@pharmaphorum.bsky.social
@pharmaphorum.bsky.socialThe #FDA has started a review of the #marketingapplication for #Takeda's #TYK2inhibitor zasocitinib in #psoriasis, setting up a decision in mid-March 2027.